Literature DB >> 23341374

Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder.

Lukas Lusuardi1, Günter Janetschek.   

Abstract

The most commonly used imaging modalities for diagnostic investigation of bladder carcinoma are contrast-enhanced computed tomography, magnetic resonance imaging, and positron emission tomography. More recently, radioisotope and fluorescence staining are being used before, or even during, open or laparoscopic surgery. We report recent results obtained with these imaging modalities and their limitations.

Entities:  

Mesh：

Year:  2013        PMID： 23341374     DOI： 10.1007/s11934-013-0304-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  44 in total

1.  Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging.

Authors:  Anuradha Saokar; Tina Islam; Marion Jantsch; Mansi A Saksena; Peter F Hahn; Mukesh G Harisinghani
Journal:  Clin Imaging       Date:  2010 Sep-Oct       Impact factor: 1.605

2.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Authors:  Andrea B Apolo; Jamie Riches; Heiko Schöder; Oguz Akin; Alisa Trout; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

3.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:  Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

4.  Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging.

Authors:  Stephan Jeschke; Lukas Lusuardi; Andy Myatt; Stephan Hruby; Christian Pirich; Guenter Janetschek
Journal:  Urology       Date:  2012-09-15       Impact factor: 2.649

5.  Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer.

Authors:  Stephan Jeschke; Avi Beri; Martin Grüll; Josef Ziegerhofer; Peter Prammer; Karl Leeb; Wolfgang Sega; Guenter Janetschek
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

Review 6.  MR imaging of the male pelvis.

Authors:  J O Barentsz; M R Engelbrecht; J A Witjes; J J de la Rosette; M van der Graaf
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

7.  Impact of aging on substrate metabolism by the human heart.

Authors:  Andrew M Kates; Pilar Herrero; Carmen Dence; Pablo Soto; Muthayyah Srinivasan; Deborah G Delano; Ali Ehsani; Robert J Gropler
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

8.  The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.

Authors:  Jonathan L Wright; Daniel W Lin; Michael P Porter
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Identification of lymphatic pathway involved in the spread of bladder cancer: Evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green.

Authors:  Shogo Inoue; Hiroaki Shiina; Yozo Mitsui; Hiroaki Yasumoto; Akio Matsubara; Mikio Igawa
Journal:  Can Urol Assoc J       Date:  2013-05-13       Impact factor: 1.862

10.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.

Authors:  Greet Swinnen; Alex Maes; Hans Pottel; Alain Vanneste; Ignace Billiet; Karl Lesage; Patrick Werbrouck
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096
View more
  1 in total

Review 1.  Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer-A Narrative Review.

Authors:  Ankit Sinha; Alexander West; John Hayes; Jeremy Teoh; Karel Decaestecker; Nikhil Vasdev
Journal:  Curr Oncol       Date:  2022-02-23       Impact factor: 3.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.